Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting
FREMONT, Calif., July 28, 2025 /PRNewswire/ -- Alamar...
SANTA ANA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the presentation of a poster entitled, “Mechanism of Action of Troculeucel (Non-genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) in Alzheimer's Disease Confirmed by Corresponding Phase I Biomarker Data” at the Alzheimer’s Association International Conference 2025 (“AAIC 2025”) held in Toronto, Canada and online from July 27-31, 2025.
Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer’s across the entire patient journey.
STEINHAGEN, Germany, July 25, 2025 /PRNewswire/ -- Plasmatreat GmbH, the global leader in atmospheric plasma technology, has unveiled HydroPlasma®, an innovative, eco-friendly solution for...
STEINHAGEN, Germany, July 25, 2025 /PRNewswire/ -- Plasmatreat GmbH, the global leader in atmospheric plasma technology, has unveiled HydroPlasma®, an innovative, eco-friendly solution for...
STEINHAGEN, Germany, July 25, 2025 /CNW/ -- Plasmatreat GmbH, the global leader in atmospheric plasma technology, has unveiled HydroPlasma®, an innovative, eco-friendly solution for...
STEINHAGEN, Germany, July 25, 2025 /PRNewswire/ -- Plasmatreat GmbH, the global leader in atmospheric plasma technology, has unveiled HydroPlasma®, an innovative, eco-friendly solution for...
DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The global Knee Replacement Surgery Market, valued at US$10.86 billion in 2023 stood at US$12.00 billion in 2025...
Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection
New findings highlight the central role of...